Analysis method for determining specific impurities in citicoline (sodium) injection

Through high-performance liquid chromatography analysis, unknown impurities in citicoline (sodium) injection were identified and measured, and the problem of impurities generated after high-temperature sterilization was solved, and the accurate detection of uridine diphosphate choline was achieved, which improved the Drug quality control and safety.

CN119023847APending Publication Date: 2024-11-26CHANGZHOU PHARMA FACTORY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411240469.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-05
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art lacks effective methods to identify and determine unknown impurities in citicoline (sodium) injections, especially degraded impurities generated during high-temperature sterilization, which affects the quality and safety of drugs.

Method used

A high-performance liquid chromatography analysis method was developed, using reverse phase octadecyl-bonded silica gel chromatography column, combining phosphate buffer and methanol as mobile phase components, and the detection wavelength was between 200-300nm, and impurities were determined by optimizing chromatographic conditions. It is uridine diphosphate choline and has been subjected to methodological verification to meet the testing requirements of the Chinese Pharmacopoeia.

Benefits of technology

Accurate detection of uridine diphosphate choline, improve the quality control level of citicoline (sodium) injection, ensure the safety of drugs and the reliability of registration and declaration, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119023847A_ABST
    Figure CN119023847A_ABST
Patent Text Reader

Abstract

The invention provides an analysis method for determining specific impurities of a citicoline (sodium) injection, citicoline (sodium) raw material medicine is relatively stable in a solid state, sterilization is needed when the citicoline (sodium) raw material medicine is prepared into the injection, uridine diphosphorylcholine can be generated as long as high-temperature sterilization is carried out, and therefore the citicoline (sodium) raw material medicine belongs to the specific impurities of the injection. According to the method, high performance liquid chromatography is adopted for determination. The method has the advantages of simplicity and convenience in operation, good specificity and accuracy, high sensitivity and the like, and is suitable for impurity determination of a citicoline (sodium) injection finished product in industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of impurity detection and analysis methods, and in particular to a high performance liquid chromatography analysis method for determining specific impurities in citicoline (sodium) injection. Background Art

[0002] Citicoline (sodium) (Citicoline or Citicoline Sodium), chemical name is choline cytosine diphosphate (monosodium salt).

[0003] Its structure is as follows:

[0004]

[0005] Citicoline (sodium) API is relatively stable in solid state. When it is made into injection, it needs to be sterilized. As long as it is sterilized at high temperature, unknown impurities will be produced, so it is a unique impurity of injection. After inquiry, only the Chinese Pharmacopoeia (2020 edition) includes the cytiphosphocholine sodium injection variety, and other national pharmacopoeias (such as the United States Pharmacopoeia, the European Pharmacopoeia, and the Japanese Pharmacopoeia) do not include it. The Chinese Pharmacopoeia includes the detection method of related substances of cytiphosphocholine sodium injection.

[0006] However, there is no detection method for this specific impurity in the Chinese Pharmacopoeia method; in addition, the control limit of other single impurities is 0.5%. In addition to the known impurity 5'-cytidylic acid, another single impurity of about 0.2% can be detected in commercial production batches (the limit required by the Chinese Pharmacopoeia is 0.5%, which meets the requirements of the Pharmacopoeia). Under this method, it is an unknown impurity, and this impurity will increase with time, indicating that this impurity is a specific impurity produced by the degradation of citicoline (sodium) injection after sterilization.

[0007] Moreover, according to the guidelines of ICH (International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use), higher requirements are put forward for injections, requiring that unknown single impurities exceeding 0.2% must be identified for impurity structure. In addition, injections are dosage forms for direct intravenous injection, and the control of impurities is more stringent than that of oral solid preparations. Therefore, it is urgent to develop an analytical method for the determination of specific impurities in citicoline (sodium) injection. Summary of the invention

[0008] In order to overcome the deficiencies of the prior art, the technical problem to be solved by the present invention is to identify unknown impurities in citicoline (sodium) injection and provide an analytical method for unknown impurities in citicoline (sodium) injection, and the established analytical method meets the requirements of methodological validation.

[0009] Citicoline (sodium) is a drug for the treatment of cerebrovascular diseases. Hot pressing sterilization is used in the production process of its injection. During the quality research of citicoline (sodium) injection, the inventor found a high content of unknown impurities. Since there are no such impurities in the raw materials, the inventor speculated that the impurities were produced during the high-temperature sterilization process. Combining a large number of experiments and literature research, the inventor judged that the unknown impurity may be a degradation impurity-uridine diphosphate choline, whose structural formula is:

[0010]

[0011] The mechanism of the generation of this impurity is: under high temperature alkaline conditions, the amino group in the chemical structure of citicoline (sodium) may be hydrolyzed into a hydroxyl group, and then tautomerized into an impurity (uridine diphosphate choline), as shown in the figure below:

[0012]

[0013] Furthermore, the inventors confirmed that the above unknown impurity was indeed uridine diphosphate choline by purchasing standard products as controls. On this basis, the inventors developed an analytical method for the determination of specific impurities in citicoline (sodium) injection.

[0014] The technical solution of the present invention to solve the above technical problems is as follows:

[0015] An analytical method for determining specific impurities in citicoline (sodium) injection comprises the following steps:

[0016] (1) Preparation of test solution;

[0017] (2) Setting of chromatographic conditions;

[0018] (3) Detection: The detection wavelength is 200-300nm,

[0019] The step (2) is detected by high performance liquid chromatography; the chromatographic conditions are: using a reverse phase octadecyl bonded silica gel chromatographic column; using phosphate buffer and methanol as mobile phase components, respectively, and performing isocratic elution, and the impurity is uridine diphosphate choline.

[0020] Preferably, the high performance liquid chromatography analysis method for determining specific impurities in citicoline (sodium) injection comprises the following steps:

[0021] (1) Preparation of test solution: Accurately measure an appropriate amount of sterilized citicoline (sodium) injection solution and dilute it with water to make a solution containing approximately 2.5 mg of citicoline per 1 ml;

[0022] (2) Chromatographic conditions: A reversed-phase octadecyl bonded silica gel column was used, the column temperature was set at 30-40°C, phosphate buffer [potassium dihydrogen phosphate solution and tetrabutylammonium solution (0.01 mol / L tetrabutylammonium hydroxide solution was taken and the pH value was adjusted to 4.5±0.05 with phosphoric acid) in equal amounts (v / v)] and methanol were used as the mobile phase components, and isocratic elution was performed at a flow rate of 0.5-1.5 ml / min, and the detection wavelength was 200-300 nm;

[0023] (3) Detection: Take the Citicoline (sodium) injection solution prepared in step (1) with an injection volume of 5-20 μl; the concentration of the potassium dihydrogen phosphate solution in the mobile phase in step (2) is 0.01-0.3 mol / L.

[0024] Preferably, the chromatographic column in step (2) is: Agilent ZORBAX SB C 18 , 4.6mm×250mm, 5μm 。

[0025] Preferably, in step (2), the isocratic elution ratio of the mobile phase is phosphate buffer:methanol (95:5).

[0026] Preferably, in step (2), the flow rate is 1.0 ml / min and the column temperature is 30°C.

[0027] Preferably, the concentration of the potassium dihydrogen phosphate solution used as the mobile phase in step (2) is 0.1 mol / L.

[0028] Preferably, the injection volume in step (3) is preferably 10 μl.

[0029] Preferably, the high performance liquid chromatography analysis method for determining specific impurities in citicoline (sodium) injection has a detection wavelength of 276 nm.

[0030] The beneficial effect of the present invention is that the inventors found that the citicoline (sodium) injection has a high content of unknown impurities. By analyzing and judging the mechanism of the production of degradation impurities after the citicoline (sodium) aqueous solution is sterilized according to the process of the injection, it is inferred and verified that the specific impurity is uridine diphosphate choline, and a high-performance liquid chromatography analysis method is further established for determination. The inventors used an octadecyl bonded silica gel chromatographic column to determine the analysis method of the present invention by optimizing the composition and proportion of the mobile phase. At the same time, according to the definition and verification method of the four general rules 0512 (high performance liquid chromatography) and general rules 9101 (drug quality standard analysis method verification guidelines) of the 2020 edition of the Chinese Pharmacopoeia, methodological verification was carried out, and the results showed that the method can be used for uridine diphosphate choline detection. All impurities in the present invention are calculated by the main component self-control method with correction factors, which has the advantages of simple and economical operation, good specificity and accuracy, and high sensitivity. This method is suitable for the industrial production of impurities in finished products of citicoline (sodium) injection. The research on the determination and analysis method of the impurity uridine diphosphate choline is conducive to improving the quality control level of citicoline (sodium) injection, and can also be used for the registration application of citicoline (sodium) injection. The quality control research of citicoline (sodium) injection is of great significance, which is conducive to improving the quality standard of citicoline (sodium) injection and improving the safety of people's medication; it will greatly promote the more in-depth and extensive research on the safety, reliability, stability and quality control of citicoline (sodium) injection related medications and the production process, and has good economic and social effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 is the system suitability map;

[0032] Figure 2 is the sample solution spectrum;

[0033] Figure 3 is the reference solution spectrum;

[0034] Among them, BLD-1 is the code name for uridine diphosphate choline; Citicoline sodium represents citicoline sodium; Cytidine-5'-monophosphate represents 5'-cytidylic acid. DETAILED DESCRIPTION

[0035] The present invention is described below with reference to examples, but the present invention is not limited thereto. In the art, simple replacement or improvement made by technicians in the field to the present invention belongs to the technical solution protected by the present invention.

[0036] Embodiment 1:

[0037] Detection instruments and chromatographic conditions:

[0038] High performance liquid chromatograph: Shimadzu LC-20A

[0039] Chromatographic column: Octadecyl bonded silica gel as filler (Agilent ZORBAX SB C 18 , 4.6mm×250mm, 5μm)

[0040] Mobile phase: phosphate buffer [0.1 mol / L potassium dihydrogen phosphate solution and tetrabutylammonium solution (0.01 mol / L tetrabutylammonium hydroxide solution adjusted to pH 4.5 with phosphoric acid) mixed in equal amounts]-methanol (95:5);

[0041] Detection wavelength: 276nm;

[0042] Flow rate: 1.0ml / min;

[0043] Column temperature: 30°C;

[0044] Injection volume: 10 μl;

[0045] Step 1, preparation of test solution: accurately measure an appropriate amount of injection solution, and dilute it quantitatively with water to make a solution containing approximately 2.5 mg of citicoline per 1 ml.

[0046] Step 2, preparation of control solution: accurately measure an appropriate amount of the test solution and dilute it quantitatively with water to make a solution containing approximately 5 μg of citicoline per 1 ml.

[0047] Step 3, preparation of system suitability solution: weigh appropriate amounts of uridine diphosphate choline and citicoline (sodium) reference substances, dissolve in water and dilute to prepare a mixed solution containing approximately 20 μg uridine diphosphate choline and 2.5 mg citicoline per 1 ml.

[0048] Step 4, determination and calculation of impurity content: System suitability requirements In the system suitability solution chromatogram, the peak order is citicoline and UDPC, and the separation between the peaks should be no less than 1.5. In the sensitivity solution chromatogram, the signal-to-noise ratio of the citicoline peak height should be no less than 10.

[0049] Determination method: Accurately measure the test solution and the reference solution, inject them into the liquid chromatograph respectively, and record the chromatogram to 2.5 times the retention time of the main peak.

[0050] Calculation: If there are impurity peaks in the chromatogram of the limit test solution, the corrected peak area of ​​uridine diphosphate choline (multiplied by the correction factor) shall not exceed 4 times the main peak area of ​​the control solution (0.8%), the peak area of ​​other individual impurity peaks shall not be greater than the main peak area of ​​the control solution (0.2%), and the sum of the peak areas of other individual impurities shall not be greater than the main peak area of ​​the control solution (0.2%). Peaks smaller than the main peak area of ​​the sensitivity solution shall be ignored.

[0051] Embodiment 2:

[0052] The relevant substances were determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).

[0053] Test solution: Accurately measure an appropriate amount of the product and dilute it quantitatively with water to make a solution containing approximately 2.5 mg of citicoline sodium per 1 ml.

[0054] Accurately measure 1 ml of the test solution, place it in a 200 ml volumetric flask, add water to dilute to the mark, and shake well.

[0055] 5'-Cytidylic acid reference solution: Take an appropriate amount of 5'-Cytidylic acid reference, weigh accurately, dissolve in water and quantitatively dilute to make a solution containing approximately 7.5 μg per 1 ml.

[0056] Citicoline sodium reference solution: Take an appropriate amount of Citicoline sodium reference, accurately weigh it, dissolve it in water and quantitatively dilute it to make a solution containing about 0.25 mg per 1 ml.

[0057] System suitability solution: Take an appropriate amount of 5'-cytidylic acid reference substance, dissolve it in water and quantitatively dilute it to make a solution containing about 0.25 mg per 1 ml. Take an appropriate amount and mix it with an equal amount of citicoline sodium reference substance solution and shake well.

[0058] Chromatographic conditions: octadecylsilane bonded silica gel was used as filler; phosphate buffer [0.1 mol / L potassium dihydrogen phosphate solution and tetrabutylammonium solution (0.01 mol / L tetrabutylammonium hydroxide solution was taken and the pH value was adjusted to 4.5 with phosphoric acid) mixed in equal amounts]-methanol (95:5) was used as mobile phase; the detection wavelength was 276 nm; the injection volume of the system suitability solution was 20 μl, and the injection volume of other solutions was 10 μl.

[0059] System suitability requirements: In the system suitability solution chromatogram, the separation degree of citicoline and 5'-cytidylic acid should meet the requirements.

[0060] Determination method: Accurately measure the test solution, control solution and 5'-cytidylic acid reference solution, inject them into the liquid chromatograph respectively, and record the chromatogram to 2.5 times the retention time of the main peak.

[0061] Limit: If there are impurity peaks in the test solution, the 5'-cytidylic acid content shall not exceed 0.3% of the labeled amount of citicoline sodium according to the peak area calculated by the external standard method; the area of ​​other single impurity peaks shall not be greater than the main peak area of ​​the control solution (0.5%), and the sum of the peak areas of other impurities shall not be greater than 1.4 times the main peak area of ​​the control solution (0.7%).

[0062] The test results of the normally produced Citicoline (sodium) injection (finished product, which must undergo a sterilization process) are as follows according to the test method of the Chinese Pharmacopoeia:

[0063]

[0064] As time goes by, the largest single impurity will increase, indicating that this impurity is a specific impurity produced by the degradation of citicoline (sodium) injection after sterilization.

[0065] Test Example 1: Methodology Verification Content

[0066] 1. Specificity test

[0067] According to the method validation requirements, the specificity test results are shown in the following table:

[0068] Specificity test results

[0069]

[0070] The specificity results showed that the chromatographic peaks of the impurity uridine diphosphate choline and the main component citicoline were well separated; neither the blank solution nor the negative injection solution showed any peaks, indicating that it did not interfere with the detection of the uridine diphosphate choline impurity.

[0071] 2. Detection limit and quantification limit test

[0072] The detection limit and quantitation limit solutions were prepared according to the method validation requirements. The results are shown in the table below:

[0073] Detection limit results table

[0074]

[0075] The results of the detection limit and quantification limit tests showed that the sensitivity (detection limit and quantification limit) of this method was both lower than 0.05%, meeting the detection requirements.

[0076] 3 Linearity test and correction factor

[0077] Weigh the appropriate amount of UDCP and Citicoline (sodium) reference substances accurately, add water to prepare linear level solutions, and prepare linear series solutions with the quantitative limit level to the test solution concentration of 1.2%. Take each linear solution, inject it into the liquid chromatograph, and record the chromatogram. Perform linear regression with the concentration of each component as the horizontal axis and the peak area as the vertical axis, and calculate the correction factor of UDCP using the ratio of the slope of Citicoline to UDCP. The data results are as follows:

[0078] Linear test results statistics table

[0079]

[0080]

[0081] The linear results showed that at the corresponding detection concentration, UDCP had a good linear relationship, and the correction factor of UDCP relative to the main component was 1.64.

[0082] The limit of unknown single impurity in the original Chinese Pharmacopoeia is 0.5%. The correction factor of this impurity is 1.64, 1.64*0.5%=0.82%, that is, the limit can be set at 0.8%.

[0083] 4 Accuracy test

[0084] The accuracy test was carried out according to the requirements of the method validation, and the results are shown in the following table:

[0085] Accuracy test results statistics table

[0086]

[0087] The accuracy test results show that the method has good accuracy in determining UDCP impurities, with each level ranging from 80.0% to 120.0%.

[0088] Conclusion: The analytical method established above meets the requirements of methodological validation and can be used for the determination of UDP-choline, a specific impurity in sterilized citicoline (sodium) injection.

[0089] The detection results of the impurity uridine diphosphate choline before and after sterilization of citicoline (sodium) injection are as follows:

[0090]

[0091] The stability results of commercial batches are shown in the table below:

[0092] Accelerated test results (test conditions: temperature 40±2℃, 75±5%RH)

[0093]

[0094] Long-term test results (test conditions: temperature 25±2℃, RH60±5%)

[0095]

[0096]

[0097] The above is only a preferred embodiment of the present invention. It should be pointed out that a person skilled in the art can make several modifications and improvements without departing from the inventive concept of the present invention, which all belong to the protection scope of the present invention.

Claims

1. An analytical method for determining specific impurities in citicoline (sodium) injection, characterized in that: The steps include: (1) Preparation of test solution; (2) Setting of chromatographic conditions; (3) Detection: The detection wavelength is 200-300nm, The step (2) is detected by high performance liquid chromatography; the chromatographic conditions are: using a reverse phase octadecyl bonded silica gel chromatographic column; using phosphate buffer and methanol as mobile phase components, respectively, and performing isocratic elution, and the impurity is uridine diphosphate choline.

2. The method according to claim 1, characterized in that The phosphate buffer is specifically: potassium dihydrogen phosphate solution and tetrabutylammonium solution are mixed in equal amounts v / v, the concentration of the potassium dihydrogen phosphate solution of the mobile phase is 0.01-0.3 mol / L, and the preparation method of the tetrabutylammonium solution is to take 0.01 mol / L tetrabutylammonium hydroxide solution and adjust the pH value to 4.5±0.05 with phosphoric acid.

3. The method according to claim 1, characterized in that The chromatographic column in step (2) is: Agilent ZORBAX SBC 18 , 4.6mm×250mm, 5μm.

4. The method according to claim 1, characterized in that: In step (2), the isocratic elution ratio of the mobile phase is phosphate buffer:methanol in a volume ratio of 95:

5.

5. The method according to claim 1, characterized in that The isocratic elution flow rate was 0.5-1.5 ml / min, and the column temperature was set at 30-40 °C.

6. The method according to claim 5, characterized in that The flow rate was 1.0 ml / min and the column temperature was 30 °C.

7. The method according to claim 1, characterized in that The test solution is prepared specifically as follows: accurately measure an appropriate amount of sterilized citicoline (sodium) injection solution, and quantitatively dilute it with water to prepare a solution containing about 2.5 mg of citicoline per 1 ml.

8. The method according to claim 1, characterized in that: The detection step (3) is specifically as follows: taking the citicoline (sodium) injection solution prepared in step (1) with an injection volume of 5-20 μl.

9. The method according to claim 8, characterized in that The injection volume in step (3) is 10 μl.

10. The method according to claim 2, characterized in that The concentration of the potassium dihydrogen phosphate solution used as the mobile phase in step (2) is 0.1 mol / L, and the detection wavelength is 276 nm.